403 Stock Overview
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 403 from our risk checks.
Pacific Shuanglin Bio-pharmacy Co., LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.69 |
| 52 Week High | CN¥31.25 |
| 52 Week Low | CN¥17.49 |
| Beta | 0.47 |
| 1 Month Change | 6.15% |
| 3 Month Change | 15.98% |
| 1 Year Change | 26.99% |
| 3 Year Change | -23.08% |
| 5 Year Change | 80.57% |
| Change since IPO | 3,052.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 403 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.7% | 0.3% | 1.6% |
| 1Y | 27.0% | -24.2% | -15.1% |
Return vs Industry: 000403 exceeded the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 000403 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 403 volatility | |
|---|---|
| 403 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 000403 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000403's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,093 | Hua Gang Yuan | www.slbiop.com |
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation.
Pacific Shuanglin Bio-pharmacy Co., LTD Fundamentals Summary
| 403 fundamental statistics | |
|---|---|
| Market cap | CN¥21.76b |
| Earnings (TTM) | CN¥612.11m |
| Revenue (TTM) | CN¥2.33b |
35.5x
P/E Ratio9.3x
P/S RatioIs 403 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 403 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.33b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥2.33b |
| Other Expenses | CN¥1.72b |
| Earnings | CN¥612.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | 26.29% |
| Debt/Equity Ratio | 6.8% |
How did 403 perform over the long term?
See historical performance and comparison